Fuji-Keizai USA, Inc., Nov 2003, Pages: 133
This report is about the worldwide market for human prescriptiondrugs as it transitions through 2003. The study provides readers with recent information and analysis about key developments driving
Fuji-Keizai USA, Inc., Feb 2005, Pages: 151
This report looks at the worldwideprescriptiondrug market for women's health and estimates the market outlook to 2009. The research study shows that, while the global economy has had its ups
PharmaVentures, Jan 2009
5 Estimated value in 2008 worldwide sales of the top 200 prescriptiondrugs by year of US patent expiry
6 Life cycle management
7 All deal activity, 1997-2008
8 Drug delivery deal activity, 1997
Global Industry Analysts, Inc., Sep 2008, Pages: 425
Disorders 118
Market Overview 118
Worldwide Leading PrescriptionDrugs for Psychotic Disorders
and Year of Patent Expiry 118
Osteoporosis 118
Market Overview 118
Multiple Sclerosis 118
Market Overview
Global Industry Analysts, Inc., July 2009, Pages: 1810
This report analyzes the worldwide markets for PrescriptionDrugs in US$ Billion by the following therapeutic class – Oncologics/ Cancer Drugs, Lipid Regulators, Respiratory Agents, Proton Pump
Global Industry Analysts, Inc., April 2011, Pages: 1088
This report analyzes the worldwide markets for Pediatric Drugs and Vaccines in US$ Million by the following Product Segments: Pediatric Vaccines, Pediatric Hormones, Allergy & Respiratory Drugs
Draco Healthcare Consulting LLC, May 2009, Pages: 103
.855 billion (USD 714 million), an increase of 22.14% from 2006
This report has systemically analyzed the Chinese asthma drug market. All drug data are based on hospital drugprescription and drug purchasing
Draco Healthcare Consulting LLC, Dec 2009, Pages: 173
systemically analyzed the Chinese anti-cancer drug market. All drug data are based on hospital drugprescription and drug purchasing data from the hospital data monitor system that the China Nan Fang Institute
UBM Canon, April 2011, Pages: 177
, and awaiting approval. Regions of development include the United States, Europe, and Japan. A directory of orthopedic prescription-drug developers and marketers is included.
Additionally provided in this report
UBM Canon, Dec 2010, Pages: 403
prescription brands are losing patent protection during a current five-year period. Prescriptiondrugs that generated nearly $100 billion in 2009 sales are running out of patent protection in the next few years
Timely Data Resources, Inc., Sep 2011, Pages: 13
Laxatives
Novel prescription treatments
Other treatments
V. DOSING AND TREATMENT COSTS
Dosing for commonly prescribed drugs
Costs for commonly prescribed drugs
VI. MARKET SIZE
Market overview
Sales
Global Industry Analysts, Inc., Feb 2010, Pages: 893
This report analyzes the worldwide markets for Anti-Hypertensive Drugs in US$ Million.
The report provides separate comprehensive analytics for US, Europe and Rest of World.
Annual forecasts
Global Industry Analysts, Inc., Oct 2011, Pages: 365
This report analyzes the worldwide markets for Anti-Obesity Drugs in US$ Million. The report provides separate comprehensive analytics for the US, Europe, and Rest of World. Annual estimates
Espicom Business Intelligence Ltd, Jan 2012, Pages: 126
million.
Tackling Opioid Abuse
Opioid abuse is a widely known problem, particularly in the US. Prescriptiondrug abuse in the US is the country’s fastest growing drug abuse problem and has been directly
Global Industry Analysts, Inc., Aug 2011, Pages: 228
, and low priced drugs, particularly to those residing in remote locations and those who are homebound either due to a disease or aging. ePharmacies are playing a significant role in the prescriptiondrugs
Bizacumen Inc., Nov 2009, Pages: 286
are presented in "Anti-Obesity Drugs: Trends & Opportunities Worldwide" by BizAcumen, Inc. Our reports are designed to be most comprehensive in geographic coverage and vertical market analyses. ANTI-OBESITY
Takeda Pacific, Oct 2004, Pages: 123
This report is about the global market for prescriptiondrugs and estimates the market outlook to 2008. Readers receive detailed data and analysis about important global pharmaceutical industry
UBM Canon, Aug 2011, Pages: 67
exceeding $5 billion. Pfizer Inc. and Eisai Co. Ltd.'s Aricept is the top-selling drug for the treatment of dementia. Aricept is the first and only prescription medication approved by the FDA
Fuji-Keizai USA, Inc., June 2010, Pages: 172
. Worldwide Biopharmaceutical Drug Market Trends, 2009-2013
3. US Biopharmaceutical Drug Market Trends
- US Sales of Biopharmaceutical Drugs by Disease Category, 2009-2013
- New Drug Market Entries by Disease
Fuji-Keizai USA, Inc., June 2010, Pages: 172
. Worldwide Biopharmaceutical Drug Market Trends, 2009-2013
3. US Biopharmaceutical Drug Market Trends
- US Sales of Biopharmaceutical Drugs by Disease Category, 2009-2013
- New Drug Market Entries by Disease
